Cite
MLA Citation
K. Park et al.. “1379TiPPhase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor.” Annals of oncology, vol. 28, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100097083735.0x00001a